Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Cai, Xin ^a   Sheng, Jianhui ^a   Tang, Chuanning ^b   Nandakumar, Vijayalakshmi ^c   Ye, Hua ^b   Ji, Hong ^a   Tang, Haiying ^a   Qin, Yu ^a   Guan, Hongwei ^a   Lou, Feng ^b   Zhang, Dandan ^b   Sun, Hong ^b   Dong, Haichao ^b   Zhang, Guangchun ^b   Liu, Zhiyuan ^b   Dong, Zhishou ^b   Guo, Baishuai ^b   Yan, He ^b   Yan, Chaowei ^b   Wang, Lu ^b   Su, Ziyi ^b   Li, Yangyang ^b   Jones, Lindsey ^c   Huang, Xue F ^c   Chen, Si Yi ^c   Wu, Taihua ^a   Lin, Hongli ^a   more..

^a DALIAN MEDICAL UNIVERSITY   (China)

^b San Valley Biotechnology Incorporated   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ANALYZER; ARTICLE; BREAST CANCER; DNA SEQUENCE; EGFR GENE; FEMALE; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; ION TORRENT DNA SEQUENCING; KRAS GENE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; ONCOGENE; TP53 GENE; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; NON SMALL CELL LUNG CANCER; NUCLEOTIDE SEQUENCE; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899762549     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095228     Document Type: Article

References (37)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
2. Bray F, Ren JS, Masuyer E, Ferlay J (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132: 1133-1145.
3. Herbst RS, Heymach JV, Lippman SM (2008) Lung Cancer. New England Journal of Medicine 359: 1367-1380.
4. Hecht SS (2003) Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 3: 733-744.
5. Thun MJ, Hannan LM, Adams-Campbell LL, Boffetta P, Buring JE, et al. (2008) Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts and 22 Cancer Registry Studies. PLoS Med 5: e185.
6. Sun S, Schiller JH, Gazdar AF (2007) Lung cancer in never smokers - a different disease. Nat Rev Cancer 7: 778-790. (Pubitemid 47463669)
7. Thun MJ, Henley SJ, Calle EE (2002) Tobacco use and cancer: an epidemiologic perspective for geneticists. Oncogene 21: 7307-7325. (Pubitemid 35314509)
8. Schmid K, Kuwert T, Drexler H (2010) Radon in indoor spaces: an underestimated risk factor for lung cancer in environmental medicine. Dtsch Arztebl Int 107: 181-186.
9. Chen H, Goldberg MS, Villeneuve PJ (2008) A systematic review of the relation between long-term exposure to ambient air pollution and chronic diseases. Rev Environ Health 23: 243-297.
10. Clapp RW, Jacobs MM, Loechler EL (2008) Environmental and occupational causes of cancer: new evidence 2005-2007. Rev Environ Health 23: 1-37. (Pubitemid 351644506)
11. Hadd AG, Houghton J, Choudhary A, Sah S, Chen L, et al. (2013) Targeted, High-Depth, Next-Generation Sequencing of Cancer Genes in Formalin-Fixed, Paraffin-Embedded and Fine-Needle Aspiration Tumor Specimens. J Mol Diagn.
12. Idbaih A, Aimard J, Boisselier B, Marie Y, Paris S, et al. (2009) Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma. Neuropathology and Applied Neurobiology 35: 208-213.
13. Kenichi Suda KT, Tetsuya Mitsudomi (2010 Mar 29) Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 29: 49-60.
14. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, et al. (2002) The IARC TP53 database: New online mutation analysis and recommendations to users. Human Mutation 19: 607-614. (Pubitemid 34556481)
15. Pfeifer G, Besaratinia A (2009) Mutational spectra of human cancer. Human Genetics 125: 493-506.
16. Ory K LY, Auguin C, Soussi T (1994) Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13: 3496-3504. (Pubitemid 24246186)
17. Sigal A, Rotter V (2000) Oncogenic Mutations of the p53 Tumor Suppressor: The Demons of the Guardian of the Genome. Cancer Research 60: 6788-6793. (Pubitemid 32059139)
18. Peart MJ, Prives C (2006) Mutant p53 gain of function: The NF-Y connection. Cancer Cell 10: 173-174. (Pubitemid 44311071)
19. Petitjean A, Achatz MIW, Borresen-Dale AL, Hainaut P, Olivier M (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26: 2157-2165. (Pubitemid 46536647)
20. Pisters KMW, Evans WK, Azzoli CG, Kris MG, Smith CA, et al. (2007) Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small-Cell Lung Cancer Guideline. Journal of Clinical Oncology 25: 5506-5518. (Pubitemid 350232227)
21. Simon GR, Turrisi A (2007) Management of small cell lung cancer*: Accp evidence-based clinical practice guidelines (2nd edition). CHEST Journal 132: 324S-339S.
22. Travis WD, World Health Organization, International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology (2004) Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon Oxford: IARC Press Oxford University Press (distributor). 344 p. p.
23. Pelosi G, Sonzogni A, Galetta D, Perrone F, Braidotti P, et al. (2011) Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type. Virchows Archiv 458: 497-503.
24. Lyon (2004) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press:.
25. Dempke WCM, Suto T, Reck M (2010) Targeted therapies for non-small cell lung cancer. Lung Cancer 67: 257-274.
26. Hannay DR (2000) The Evidence-Based Primary Care Handbook. BMJ 321: 576.
27. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. New England Journal of Medicine 353: 123-132. (Pubitemid 41058344)
28. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, et al. (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. The Lancet 373: 1525-1531.
29. Ninomiya T, Takigawa N, Ichihara E, Ochi N, Murakami T, et al. (2013) Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model. Molecular Cancer Therapeutics 12: 589-597.
30. Sun Y, Nowak KA, Zaorsky NG, Winchester C-L, Dalal K, et al. (2013) ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non-Small Cell Lung Cancer Expressing EML4-ALK. Molecular Cancer Therapeutics 12: 696-704.
31. Rosell R, Lord RVN, Taron M, Reguart N (2002) DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38: 217-227. (Pubitemid 35341796)
32. Adjei AA (2004) Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent. Clinical Cancer Research 10: 4276s-4280s.
33. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, et al. (2005) Vinorelbine plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer. New England Journal of Medicine 352: 2589-2597. (Pubitemid 41007845)
34. Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Prac Oncol 3: 24-40. (Pubitemid 43108832)
35. Genomes Project C, Abecasis GR, Altshuler D, Auton A, Brooks LD, et al. (2010) A map of human genome variation from population-scale sequencing. Nature 467: 1061-1073.
36. Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (Available: http://evs.gs.washington.edu/EVS/) Accessed 2013 March 19.
37. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, et al. (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91: 355-358. (Pubitemid 39037083)